The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Women are increasingly taking the lead at grand rounds, however, female grand lecturers are still markedly underrepresented ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.